eribulin mesylate的药理与临床研究

Progress on pharmacology and clinical research of eribulin mesylate

通过文献回顾,评价eribulin mesylate治疗转移性乳腺癌中的药理作用、药动学、临床研究和安全性。本品作为微管抑制剂,临床试验结果显示,对化疗药物产生多重耐药性的转移性乳腺癌具有很好的疗效,主要的不良反应为中性粒细胞减少症。本品可延长转移性乳腺癌患者的总存活时间,更多的研究有待进一步的评价。

By literature review, pharmacology, pharmacokinetics, clinical study, and safety of eribulin mesylate in the treatment of metastatic breast cancer （MBC） were evaluated in the paper. As a microtubule inhibitor, eribulin mesylate has a good effect on multiple drug resistance of chemotherapy medicines in patients with MBC. The main adverse drug reaction is neutropenia. Eribulin mesylate could extend overall survival in patients with MBC. However, further studies should be conducted.